A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.

John A Dougherty Erenie H Guirguis Krisy-Ann Thornby

Published in: The Annals of pharmacotherapy (2020)

Based on study data utilizing imaging studies and biopsy results, GLP-1 RAs or SGLT2 inhibitors can benefit NAFLD T2DM patients. Clinical trials with larger patient populations may augment these results.

Keyphrases

clinical trial
end stage renal disease
ejection fraction
high resolution
peritoneal dialysis
big data
case report
machine learning
randomized controlled trial
ultrasound guided
artificial intelligence
insulin resistance
photodynamic therapy
phase ii